ClinicalTrials.gg
RecruitingNCT07435012MATTUpdated Mar 16, 2026

Androgenic Alopecia TH07 Clinical Trial

A Phase 3 interventional study of TH07 and TH07 in Androgenic Alopecia, sponsored by Triple Hair Inc. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Triple Hair Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Alopecia with a site in Canada — 4 open to participants now, 5 under way, 4 of them phase 3. Alopecia · Canada.

Planned enrollment
8th of 17
420 · median 322
Started
2026
with 1 other
Phase 3
7 of 18
3 open now
Registered
17th of 18
by date

Among the 18 studies in Alopecia with a site in Canada, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 17th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

4 of the 18 studies in Alopecia with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 49 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Alopecia with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.

Read the detailed description

The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.

TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.

Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.

The treatment will be applied daily (once or twice) for 24 weeks.

03

Conditions studied

  • Androgenic Alopecia

Browse trials for

Keywords

  • Hair Loss
  • Hair growth
  • Androgenic Alopecia
  • Balding
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, 18 to 49 years of age on the date of enrollment.
  • Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
  • (BMI) in the range of 19 to 35 kg/m2.
  • Not administered any systemic or topical treatment for AGA during the last 90 days.
  • Willing to comply with the following restrictions for the duration of trial participation:

    1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
    2. Hair dyes, hair texturizers, relaxers etc.
    3. Any new vitamins or nutritional supplements that are currently not being administered.
    4. Tattooing in the trial target area.
    5. Blood donations.
    6. OTC hair restorers.
    7. Do not expose your pregnant partner to your hands/skin where the drug might be present.
    8. Participation in any other drug or device trials during the course of this trial.

      Note: However, the following shall be permissible:

    9. Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
    10. Current regimen (if any) of vitamins and nutritional supplements.
  • Willing and able to provide written for participation in the trial and to comply with all trial requirements.
  • Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.

Exclusion criteria

Exclusion Criteria:

  • History of scalp treatment including though not limited to any of the following:

    1. Hair transplant or extension surgery.
    2. Hair weaving.
    3. Laser or light therapy on the scalp in the last 6 months.
    4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.

    5-Any other surgical treatment for hair loss

  • Any of the following hair styles:

    1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.

  • Known or presumed to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
  • Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
  • History or likelihood of use of any of the specified medicines.
  • History or clinical diagnosis of any of the specified medical conditions.
  • Participation in any or marketed drug or device trial in the last 90 days prior to screening for this trial.
  • Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Arm A

    All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks

    Drug: TH07

  • Experimental
    Arm B

    All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks

    Drug: TH07

  • Active comparator
    Arm C

    All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks

    Drug: Minoxidil 5% Topical Solution

  • Placebo comparator
    Arm D

    All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks

    Other: Placebo

Interventions

  • DrugTH07

    TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day

  • DrugTH07

    * TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day

  • Minoxidil 5%; topical solution; twice a day

  • OtherPlacebo

    Placebo; topical solution; twice a day

06

What researchers measure

Primary outcomes

  1. Non-vellus hair count

    Number of hair in the matched target area measured by phototrichogram

    Time frame: Baseline and week 24

Secondary outcomes

  1. Hair diameter and cumulative hair thickness

    hair thickness is defined as average hair diameter \* hair count in the matched target area / size of matched target area (mm/cm2)

    Time frame: Baseline and week 24

  2. Subject-reported improvement

    self-assessment questionnaire

    Time frame: week 24

  3. Non-vellus hair count

    in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo

    Time frame: Baseline and week 24

  4. Incidence of treatment related adverse events.

    reporting of adverse events and serious adverse events

    Time frame: through study completion, average 28 weeks

07

Study locations

1 of 1 sites recruiting
  • YVR Aesthetic Training and Study Centre.
    Vancouver, British Columbia V5Z1H2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 27, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07435012
Lead sponsor
Triple Hair Inc
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Edouard AL-Chami
Contact
ealchami@triplehair.ca
647-453-3253
Lori Hebert
Contact
lhebert@triplehair.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion